| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | 0.069 | 0.7 |